Canada Markets closed

Gan & Lee Pharmaceuticals. (603087.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
Add to watchlist
41.32+0.35 (+0.85%)
At close: 03:00PM CST

Gan & Lee Pharmaceuticals.

No. 8, Nanfeng West 1st Street
Huoxian Town Tongzhou District
Beijing 101109
86 10 8059 3699

IndustryMedical Instruments & Supplies
Full Time Employees3,278

Key Executives

NameTitlePayExercisedYear Born
Mr. Gan ZhongruFounder, Chairman and Chief Exec. OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.


Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

Corporate Governance

Gan & Lee Pharmaceuticals.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.